Paper Details

  1. Home
  2. Paper Details

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.

Author: BrownSarah Jane, DahmPhilipp, GuptaShilpa, KonetyBadrinath R, KunathFrank, OestreichMakinna C, SathianathenNiranjan J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Androgen deprivation therapy (ADT) is a standard treatment for advanced prostate cancer. While a medication called abiraterone has been used when ADT stops working, it's now being tested for earlier use, when the cancer is still hormone-sensitive. This study explores the potential benefits of abiraterone when used earlier in the course of prostate cancer treatment.
Paper Details　
Original Abstract of the Article :
Systemic androgen deprivation therapy (ADT), also referred to as hormone therapy,àhas long been the primary treatment for metastatic prostate cancer. Additional agents have been reserved for the castrate-resistant disease stage when ADT start becoming less effective. Abiraterone is an agent with a...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8092456/

データ提供：米国国立医学図書館（NLM）

Abiraterone Acetate: A New Frontier in Prostate Cancer Treatment

The [Treatment of prostate cancer] is a rapidly evolving field of [Oncology]. This research examines the [Potential] of [Abiraterone acetate] in combination with [Androgen deprivation therapy (ADT)] for [Metastatic hormone-sensitive prostate cancer]. This study aimed to compare the [Effectiveness] of [Abiraterone acetate + ADT] to [ADT alone] in this setting. The study found that [Abiraterone acetate + ADT] showed [Promise] in [Managing metastatic hormone-sensitive prostate cancer]. This study provides [Encouraging evidence] for the [Therapeutic potential] of [Abiraterone acetate] in this [Specific patient population].

Exploring New Territories in Prostate Cancer Treatment: The Role of Abiraterone Acetate

This study is a [Journey] into the [Desert of prostate cancer treatment]. The researchers are [Exploring new treatment strategies] to [Improve outcomes] for [Men with metastatic hormone-sensitive prostate cancer]. The [Findings] suggest that [Abiraterone acetate] may be a [Valuable addition] to [Standard ADT], offering [Hope] for [Improved disease control].

A Promising New Weapon in the Fight Against Prostate Cancer

This research provides [Encouraging news] for [Individuals diagnosed with prostate cancer]. The [Potential benefits] of [Abiraterone acetate] in [Combination with ADT] offer a [New and promising treatment option] for [Managing this challenging disease]. While [Further research] is needed to fully understand the [Long-term effects] of this [Combination therapy], these [Early findings] are [Encouraging] and offer [Hope] for the [Future of prostate cancer treatment].

Dr.Camel's Conclusion

This research explores the potential of abiraterone acetate in combination with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer. The findings suggest that this combination therapy may be a promising new treatment option for managing this challenging disease, offering hope for improved disease control and patient outcomes. Further research is needed to fully evaluate the long-term efficacy and safety of this approach.

Date :
  1. Date Completed 2021-01-15
  2. Date Revised 2022-09-22
Further Info :

Pubmed ID

33314020

DOI: Digital Object Identifier

PMC8092456

Related Literature

Article Analysis
・Effective treatment of prostate cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.